These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11761263)

  • 41. Sequential cytogenetic and molecular cytogenetic characterization of an SV40T-immortalized nasopharyngeal cell line transformed by Epstein-Barr virus latent membrane protein-1 gene.
    Zhang H; Tsao SW; Jin C; Strömbeck B; Yuen PW; Kwong YL; Jin Y
    Cancer Genet Cytogenet; 2004 Apr; 150(2):144-52. PubMed ID: 15066322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immortalization of Epstein-Barr virus-negative human B lymphocytes with minimal chromosomal instability.
    Yamashita Y; Tsurumi T; Mori N; Kiyono T
    Pathol Int; 2006 Nov; 56(11):659-67. PubMed ID: 17040288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sensitization to the lysosomal cell death pathway upon immortalization and transformation.
    Fehrenbacher N; Gyrd-Hansen M; Poulsen B; Felbor U; Kallunki T; Boes M; Weber E; Leist M; Jäättelä M
    Cancer Res; 2004 Aug; 64(15):5301-10. PubMed ID: 15289336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine.
    Havre PA; O'Reilly S; McCormick JJ; Brash DE
    Cancer Res; 2002 Mar; 62(5):1443-9. PubMed ID: 11888918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.
    Kogan I; Goldfinger N; Milyavsky M; Cohen M; Shats I; Dobler G; Klocker H; Wasylyk B; Voller M; Aalders T; Schalken JA; Oren M; Rotter V
    Cancer Res; 2006 Apr; 66(7):3531-40. PubMed ID: 16585177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell substrates: lessons learned and challenges remaining.
    Petricciani JC
    Dev Biol Stand; 1999; 100():57-63. PubMed ID: 10616176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved techniques for immortalizing animal cells.
    McLean JS
    Trends Biotechnol; 1993 Jun; 11(6):232-8. PubMed ID: 7763819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Transforming activity of DNA and proteins in continuous cell cultures and the safety of biologicals].
    Bektimitov TA
    Vopr Virusol; 1987; 32(5):519-24. PubMed ID: 3324478
    [No Abstract]   [Full Text] [Related]  

  • 49. Cell substrates. Their use in the production of vaccines and other biologicals. Past achievements - future expectations.
    Meyer HM
    Adv Exp Med Biol; 1979; 118():1-5. PubMed ID: 495259
    [No Abstract]   [Full Text] [Related]  

  • 50. Adventitious agent issues.
    Minor P
    Dev Biol (Basel); 2001; 106():409-14; discussion 414-6, 465-75. PubMed ID: 11761256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular insights to cellular mortality and immortalization.
    Kaul SC; Mitsui Y; Wadhwa R
    Indian J Exp Biol; 1998 Apr; 36(4):345-52. PubMed ID: 9717442
    [No Abstract]   [Full Text] [Related]  

  • 52. Proceedings of the Joint ESACT -- IABS meeting on the use of heteroploid and other cell substrates for the production of biologicals. Heidelberg (F.R. Germany) 18-22 May, 1981.
    Dev Biol Stand; 1981; 50():1-398. PubMed ID: 7341286
    [No Abstract]   [Full Text] [Related]  

  • 53. Major issues associated with the use of cell substrates for the production of vaccines.
    Griffiths E
    Dev Biol (Basel); 2001; 106():25-35; discussion 35-6. PubMed ID: 11761238
    [No Abstract]   [Full Text] [Related]  

  • 54. Symposium on Continuous Cell Lines as Substrates for Biologicals. Arlington, Virginia, USA (Washington, D.C.), May 26-29, 1988. Proceedings.
    Dev Biol Stand; 1989; 70():1-304. PubMed ID: 2759343
    [No Abstract]   [Full Text] [Related]  

  • 55. Practical Use of Immortalized Cells in Medicine: Current Advances and Future Perspectives.
    Voloshin N; Tyurin-Kuzmin P; Karagyaur M; Akopyan Z; Kulebyakin K
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conditionally immortalized cell lines as model systems for high-throughput biology in drug discovery.
    Daniele N; Halse R; Grinyo E; Yeaman SJ; Shepherd PR
    Biochem Soc Trans; 2002 Aug; 30(4):800-2. PubMed ID: 12196201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell substrates. Their use in the production of vaccines and other biologicals. Benefit-risk assessment.
    Dull HB
    Adv Exp Med Biol; 1979; 118():187-93. PubMed ID: 495265
    [No Abstract]   [Full Text] [Related]  

  • 58. Cell substrates. Their use in the production of vaccines and other biologicals.
    Adv Exp Med Biol; 1979; 118():1-220. PubMed ID: 40404
    [No Abstract]   [Full Text] [Related]  

  • 59. [Safety of biologicals produced in continuous cell cultures].
    Vopr Virusol; 1987; 32(5):631-2. PubMed ID: 3433720
    [No Abstract]   [Full Text] [Related]  

  • 60. Need for molecular characterization in immortalized cell lines.
    A TR
    Oral Oncol; 2017 Aug; 71():188. PubMed ID: 28652009
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.